Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SB 222200

Known as: SB-222200 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Lead optimisation starting from the previously reported selective quinoline NK(3) receptor antagonists talnetant 2 (SB-223412… Expand
2009
2009
Acute activation or blockade of neurokinin-3 (NK-3) receptors has been shown to alter dopamine-mediated function and behaviors… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2008
2008
Neuropeptide tachykinins (substance P, neurokinin A, and neurokinin B) are present in peripheral terminals of sensory nerve… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2008
2008
Tachykinin neurokinin 3 receptor (NK3R) signaling has a broad role in vasopressin (VP) and oxytocin (OT) release. Hydralazine… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2007
2007
Activation of the neurokinin 3 receptor (NK3R) by a receptor agonist, hypotension, and hyperosmolarity results in the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2006
2006
The neurokinin 3 receptor (NK3R) is colocalized with vasopressinergic neurons within the hypothalamic paraventricular nucleus… Expand
2005
2005
The anti-emetic activity of selective NK-1 receptor antagonism is well established. However, little is known of the possibility… Expand
2002
2002
The tachykinin neurokinin B (NKB) has been implicated in the hypertension that characterises pre‐eclampsia, a condition where… Expand
Highly Cited
2000
Highly Cited
2000
The pharmacological and pharmacokinetic profile of SB-222200 [(S)-(-)-N-(alpha-ethylbenzyl)-3-methyl-2-phenylquinoline-4-car… Expand
  • table 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5